Aptahem’s activities continue according to plan

Aptahem had planned to participate in both BIO Europe Spring and ISICEM during March, but one has been cancelled and the other postponed for six months due to the risk of spreading the Corona virus.

The meetings that Aptahem had booked in connection with the BIO Europe conference with representatives from, among others, Pharma companies will still happen but via other channels. Aptahem have arranged video meetings, and the first one will take place already this week.

ISICEM, the scientific conference within intensive care that Aptahem planned to attend, has been moved to September 2020. Aptahem have submitted an ePoster presenting the latest scientific findings regarding Apta-1, which would have been displayed and orally presented at the conference. Aptahem will now look into alternative options for publication and presentation of these results. More information will follow regarding the outcome of these possibilities.

Aptahem’s other ongoing activities at this stage will not be affected as a consequence of the restrictions due to the Corona virus as the company already works in a strong virtual structure. Contacts with collaborators, contractors and others will continue to take place via telephone, email and digital meetings.

For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Email: ml@aptahem.com

About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.